[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1980

Treatment of Acute and Chronic Congestive Heart Failure by Vasodilator-Afterload Reduction

Author Affiliations

From the Section of Cardiovascular Medicine, Department of Medicine (Drs Mason, Awan, Joye, Lee, DeMaria, and Amsterdam), and the Department of Physiology (Dr Mason), University of California, Davis, School of Medicine and Medical Center.

Arch Intern Med. 1980;140(12):1577-1581. doi:10.1001/archinte.1980.00330230023008
Abstract

Management of congestive heart failure is based on recognition of the specific underlying cardiac disease, understanding of the pathophysiology involved, exclusion of extracardiac complicating factors perpetuating cardiovascular dysfunction, complete information concerning available prophylactic measures, and thorough knowledge of medical and surgical therapy. Although most patients respond favorably to conventional treatment consisting of digitalis and diuretics, relatively refractory heart failure may develop in advanced myocardial heart disease (the specific, idiopathic, and ischemic cardiomyopathies) unamenable to operative intervention. The most important recent advance in the medical therapy for such patients with acute and chronic pump dysfunction has been the application of systemic vasodilator drugs to reduce excessive left ventricular afterload, thereby improving lowered cardiac output and decreasing elevated pulmonary venous pressure.

RATIONALE OF AFTERLOAD REDUCTION THERAPY  The cardiac output delivered from the intact heart is governed by integration of four principal determinants: (1) preload (ventricular end-diastolic volume), (2) contractility (variable force of

First Page Preview View Large
First page PDF preview
First page PDF preview
×